Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Expected to Announce Earnings of -$1.73 Per Share

Brokerages predict that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) will announce ($1.73) earnings per share for the current quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings. The highest EPS estimate is ($1.46) and the lowest is ($2.21). Ultragenyx Pharmaceutical reported earnings of ($2.03) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 14.8%. The firm is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($6.57) per share for the current fiscal year, with EPS estimates ranging from ($7.92) to ($4.74). For the next fiscal year, analysts anticipate that the firm will post earnings of ($4.79) per share, with EPS estimates ranging from ($6.16) to ($2.93). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last posted its quarterly earnings data on Thursday, February 10th. The biopharmaceutical company reported ($1.79) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.47). The firm had revenue of $83.39 million for the quarter, compared to analysts’ expectations of $83.68 million. Ultragenyx Pharmaceutical had a negative return on equity of 44.24% and a negative net margin of 129.20%. The company’s revenue for the quarter was down 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.34) earnings per share.

Several equities analysts have weighed in on the company. Credit Suisse Group raised Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $99.00 to $105.00 in a research note on Wednesday, March 16th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating and set a $75.00 price target on the stock in a research note on Tuesday, February 15th. StockNews.com initiated coverage on Ultragenyx Pharmaceutical in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Morgan Stanley cut their price target on Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a research note on Friday, February 11th. Finally, JPMorgan Chase & Co. upgraded Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a $132.00 price target for the company in a report on Friday, February 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $122.27.

Shares of RARE stock opened at $85.40 on Wednesday. Ultragenyx Pharmaceutical has a 1-year low of $61.21 and a 1-year high of $119.54. The stock’s fifty day simple moving average is $71.23 and its 200-day simple moving average is $76.69.

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,498 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, March 1st. The stock was sold at an average price of $66.62, for a total value of $299,656.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Thomas Richard Kassberg sold 10,281 shares of the stock in a transaction that occurred on Friday, March 11th. The shares were sold at an average price of $67.01, for a total transaction of $688,929.81. The disclosure for this sale can be found here. Insiders sold 24,289 shares of company stock worth $1,602,749 over the last quarter. 6.70% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the business. Nordea Investment Management AB lifted its stake in Ultragenyx Pharmaceutical by 19.0% in the first quarter. Nordea Investment Management AB now owns 9,151 shares of the biopharmaceutical company’s stock valued at $660,000 after acquiring an additional 1,459 shares during the last quarter. Privium Fund Management UK Ltd acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $8,579,000. Norges Bank bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $52,268,000. Barclays PLC lifted its position in Ultragenyx Pharmaceutical by 396.9% during the fourth quarter. Barclays PLC now owns 23,430 shares of the biopharmaceutical company’s stock worth $1,970,000 after purchasing an additional 18,715 shares during the period. Finally, JustInvest LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 113.2% during the 4th quarter. JustInvest LLC now owns 13,086 shares of the biopharmaceutical company’s stock worth $1,100,000 after acquiring an additional 6,947 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile (Get Rating)

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII.

Featured Stories